Ocular Therapeutix, Inc. Completes Enrollment in Phase II Study for Sustained Release Dexamethasone

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. announced today it has completed enrollment for its sustained release dexamethasone (OTX-DP) in a Phase II study under an Investigational New Drug (IND) submission to the Food and Drug Administration (FDA).

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC